Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
Identifieur interne : 000058 ( Main/Corpus ); précédent : 000057; suivant : 000059Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
Auteurs : Karla A. Lee ; Heather M. Shaw ; Veronique Bataille ; Paul Nathan ; Tim D. SpectorSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2020.
Abstract
Immune-checkpoint inhibitors (ICIs) have revolutionised the therapeutic landscape for multiple malignancies and the health of the gut microbiome (GM) is strongly linked with therapeutic responses to ICI. This review explores the implications of diet and medication on the GM for patients receiving ICI. Clinical trials are underway to explore the impact of factors such as faecal microbiota transfer, probiotics, prebiotics, bacteria consortia and a number of dietary interventions on patients receiving ICI. Randomised controlled trials are lacking, and inferences are currently based on short-term clinical and observational studies. Antibiotics should be avoided before ICI initiation, and depending on prospective data, future consideration may be given to temporary delay of initiation of non-urgent ICI if patient has had broad spectrum antibiotics within 1 month of planned treatment initiation. Proton pump inhibitor use should be discontinued when not clearly indicated and potential switch to a histamine H2-receptor antagonist considered. Patients should be advised to minimise animal meat intake and maximise plants, aiming to consume ≥30 plant types weekly. A high fibre intake (>30 g/day) has been seen to be beneficial in increasing the chance of ICI response. Fermented foods may have a beneficial effect on the GM and should be introduced where possible. Ideally, all patients should be referred to a nutritionist or dietician with knowledge of GM before commencing ICI.
DOI: 10.1016/j.ejca.2020.07.026
PubMed: 32889369
Links to Exploration step
pubmed:32889369Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.</title><author><name sortKey="Lee, Karla A" sort="Lee, Karla A" uniqKey="Lee K" first="Karla A" last="Lee">Karla A. Lee</name><affiliation><nlm:affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK; Department of Medical Oncology, The Royal Marsden, London, UK. Electronic address: karla.lee@kcl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Shaw, Heather M" sort="Shaw, Heather M" uniqKey="Shaw H" first="Heather M" last="Shaw">Heather M. Shaw</name><affiliation><nlm:affiliation>Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK; Early Phase Trial Unit, Department of Medical Oncology, University College London Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bataille, Veronique" sort="Bataille, Veronique" uniqKey="Bataille V" first="Veronique" last="Bataille">Veronique Bataille</name><affiliation><nlm:affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Dermatology, Mount Vernon Hospital, Northwood, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name><affiliation><nlm:affiliation>Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Spector, Tim D" sort="Spector, Tim D" uniqKey="Spector T" first="Tim D" last="Spector">Tim D. Spector</name><affiliation><nlm:affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32889369</idno><idno type="pmid">32889369</idno><idno type="doi">10.1016/j.ejca.2020.07.026</idno><idno type="wicri:Area/Main/Corpus">000058</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000058</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.</title><author><name sortKey="Lee, Karla A" sort="Lee, Karla A" uniqKey="Lee K" first="Karla A" last="Lee">Karla A. Lee</name><affiliation><nlm:affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK; Department of Medical Oncology, The Royal Marsden, London, UK. Electronic address: karla.lee@kcl.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Shaw, Heather M" sort="Shaw, Heather M" uniqKey="Shaw H" first="Heather M" last="Shaw">Heather M. Shaw</name><affiliation><nlm:affiliation>Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK; Early Phase Trial Unit, Department of Medical Oncology, University College London Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bataille, Veronique" sort="Bataille, Veronique" uniqKey="Bataille V" first="Veronique" last="Bataille">Veronique Bataille</name><affiliation><nlm:affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Dermatology, Mount Vernon Hospital, Northwood, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name><affiliation><nlm:affiliation>Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Spector, Tim D" sort="Spector, Tim D" uniqKey="Spector T" first="Tim D" last="Spector">Tim D. Spector</name><affiliation><nlm:affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immune-checkpoint inhibitors (ICIs) have revolutionised the therapeutic landscape for multiple malignancies and the health of the gut microbiome (GM) is strongly linked with therapeutic responses to ICI. This review explores the implications of diet and medication on the GM for patients receiving ICI. Clinical trials are underway to explore the impact of factors such as faecal microbiota transfer, probiotics, prebiotics, bacteria consortia and a number of dietary interventions on patients receiving ICI. Randomised controlled trials are lacking, and inferences are currently based on short-term clinical and observational studies. Antibiotics should be avoided before ICI initiation, and depending on prospective data, future consideration may be given to temporary delay of initiation of non-urgent ICI if patient has had broad spectrum antibiotics within 1 month of planned treatment initiation. Proton pump inhibitor use should be discontinued when not clearly indicated and potential switch to a histamine H2-receptor antagonist considered. Patients should be advised to minimise animal meat intake and maximise plants, aiming to consume ≥30 plant types weekly. A high fibre intake (>30 g/day) has been seen to be beneficial in increasing the chance of ICI response. Fermented foods may have a beneficial effect on the GM and should be introduced where possible. Ideally, all patients should be referred to a nutritionist or dietician with knowledge of GM before commencing ICI.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">32889369</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur J Cancer</ISOAbbreviation></Journal><ArticleTitle>Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.</ArticleTitle><Pagination><MedlinePgn>149-155</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(20)30426-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2020.07.026</ELocationID><Abstract><AbstractText>Immune-checkpoint inhibitors (ICIs) have revolutionised the therapeutic landscape for multiple malignancies and the health of the gut microbiome (GM) is strongly linked with therapeutic responses to ICI. This review explores the implications of diet and medication on the GM for patients receiving ICI. Clinical trials are underway to explore the impact of factors such as faecal microbiota transfer, probiotics, prebiotics, bacteria consortia and a number of dietary interventions on patients receiving ICI. Randomised controlled trials are lacking, and inferences are currently based on short-term clinical and observational studies. Antibiotics should be avoided before ICI initiation, and depending on prospective data, future consideration may be given to temporary delay of initiation of non-urgent ICI if patient has had broad spectrum antibiotics within 1 month of planned treatment initiation. Proton pump inhibitor use should be discontinued when not clearly indicated and potential switch to a histamine H2-receptor antagonist considered. Patients should be advised to minimise animal meat intake and maximise plants, aiming to consume ≥30 plant types weekly. A high fibre intake (>30 g/day) has been seen to be beneficial in increasing the chance of ICI response. Fermented foods may have a beneficial effect on the GM and should be introduced where possible. Ideally, all patients should be referred to a nutritionist or dietician with knowledge of GM before commencing ICI.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Karla A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK; Department of Medical Oncology, The Royal Marsden, London, UK. Electronic address: karla.lee@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK; Early Phase Trial Unit, Department of Medical Oncology, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bataille</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Dermatology, Mount Vernon Hospital, Northwood, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathan</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Mount Vernon Hospital, Northwood, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spector</LastName><ForeName>Tim D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">Gut microbiome</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">Microbiota</Keyword><Keyword MajorTopicYN="N">Nutrition</Keyword></KeywordList><CoiStatement>Conflict of interest statement The authors feel there are no conflicts relevant to this letter, but here are their conflicts: K.A.L. has nothing to disclose. T.D.S. has nothing to disclose. H.S. reports personal fees from Novartis, MSD, BMS, Sanofi-Genzyme, Genmab, clinical/data manager funding from Roche, Merck, Immunocore; project manager funding from BMS, NMP funding from Novartis. V.B. reports personal fees from BMS and Novartis. P.N. reports personal fees from AstraZeneca, BMS, Merck, Immunocore, Pfizer, Ipsen, 4SC, Pierre Fabre and Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>01</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>5</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32889369</ArticleId><ArticleId IdType="pii">S0959-8049(20)30426-3</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2020.07.026</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32889369
|texte= Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32889369" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |